Literature DB >> 19304864

An investigation of bupropion substitution for the interoceptive stimulus effects of nicotine.

J L Wilkinson1, F I Carroll, R A Bevins.   

Abstract

Although the exact mechanism that makes bupropion hydrochloride (Zyban) effective as a smoking cessation aid has not been fully elucidated, studies have found that bupropion and nicotine share behavioural and neurophysiological properties suggesting that bupropion might serve as a substitute for nicotine. In fact, bupropion prompts nicotine-appropriate responding in operant and Pavlovian drug discrimination studies with rats. A majority of the literature examining this substitution pattern has been done with an operant paradigm. The present research extended this literature by further characterising the behavioural and neuropharmacological properties underlying the substitution for a nicotine conditioned stimulus (CS). Examination of the dose-effect function and temporal dynamics of this substitution pattern showed that bupropion (20 mg/kg) produced conditioned responding similar to nicotine (0.4 mg base/kg) (ED(50) = 9.9 mg/kg) at 15 and 30 min after injection and partially substituted 5 and 60 min post-injection. Bupropion produced a pattern of conditioned responding similar to nicotine during a 60-min extinction test. Additionally, it has been hypothesised that bupropion and nicotine have an overlapping dopaminergic mechanism. We tested the effects of bupropion pretreatment, the nicotine dose-effect function and the ability of dopamine antagonist to block the substitution of bupropion for nicotine. Pretreatment with doses of bupropion that did not substitute for the nicotine stimulus (5 and 10 mg/kg) did not affect nicotine-conditioned responding; pretreatment with 20 mg/kg attenuated nicotine-evoked responding. Pretreatment with the dopamine antagonists SCH-23390 and eticlopride blocked the substitution. Finally, S,S-hydroxybupropion, the major metabolite of bupropion in humans, did not substitute for the nicotine CS.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19304864      PMCID: PMC2921933          DOI: 10.1177/0269881109102518

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  51 in total

1.  Applying extinction research and theory to cue-exposure addiction treatments.

Authors:  Cynthia A Conklin; Stephen T Tiffany
Journal:  Addiction       Date:  2002-02       Impact factor: 6.526

Review 2.  Context, ambiguity, and unlearning: sources of relapse after behavioral extinction.

Authors:  Mark E Bouton
Journal:  Biol Psychiatry       Date:  2002-11-15       Impact factor: 13.382

3.  Nicotine-conditioned locomotor activity in rats: dopaminergic and GABAergic influences on conditioned expression.

Authors:  R A Bevins; J Besheer; K S Pickett
Journal:  Pharmacol Biochem Behav       Date:  2001-01       Impact factor: 3.533

4.  Cigarette smoking among adults--United States, 2000.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2002-07-26       Impact factor: 17.586

5.  Bupropion is a nicotinic antagonist.

Authors:  J E Slemmer; B R Martin; M I Damaj
Journal:  J Pharmacol Exp Ther       Date:  2000-10       Impact factor: 4.030

Review 6.  Cellular mechanisms of nicotine addiction.

Authors:  J A Dani; M De Biasi
Journal:  Pharmacol Biochem Behav       Date:  2001-12       Impact factor: 3.533

7.  Nicotine and bupropion share a similar discriminative stimulus effect.

Authors:  Richard Young; Richard A Glennon
Journal:  Eur J Pharmacol       Date:  2002-05-17       Impact factor: 4.432

8.  Nicotine-like discriminative stimulus effects of bupropion in rats.

Authors:  Jenny L Wiley; Kari L Lavecchia; Billy R Martin; M Imad Damaj
Journal:  Exp Clin Psychopharmacol       Date:  2002-05       Impact factor: 3.157

9.  Examination of GABAergic and dopaminergic compounds in the acquisition of nicotine-conditioned hyperactivity in rats.

Authors:  Matthew I Palmatier; Rick A Bevins
Journal:  Neuropsychobiology       Date:  2002       Impact factor: 2.328

10.  Bupropion inhibits nicotine-evoked [(3)H]overflow from rat striatal slices preloaded with [(3)H]dopamine and from rat hippocampal slices preloaded with [(3)H]norepinephrine.

Authors:  Dennis K Miller; Sangeetha P Sumithran; Linda P Dwoskin
Journal:  J Pharmacol Exp Ther       Date:  2002-09       Impact factor: 4.030

View more
  14 in total

1.  Diminished conditioned responding to the nicotine stimulus by antidepressant drugs with differing specificity for the serotonin and norepinephrine transporter.

Authors:  Amanda M Dion; Scott C Sanderson; L Charles Murrin; Rick A Bevins
Journal:  Pharmacol Biochem Behav       Date:  2011-10-08       Impact factor: 3.533

2.  Interoceptive conditioning in rats: effects of using a single training dose or a set of 5 different doses of nicotine.

Authors:  Steven T Pittenger; Rick A Bevins
Journal:  Pharmacol Biochem Behav       Date:  2013-11-05       Impact factor: 3.533

3.  Does Extended Pre Quit Bupropion Aid in Extinguishing Smoking Behavior?

Authors:  Larry W Hawk; Rebecca L Ashare; Jessica D Rhodes; Jason A Oliver; Kenneth Michael Cummings; Martin C Mahoney
Journal:  Nicotine Tob Res       Date:  2015-01-14       Impact factor: 4.244

4.  Pharmacologic characterization of a nicotine-discriminative stimulus in rhesus monkeys.

Authors:  Colin S Cunningham; Martin A Javors; Lance R McMahon
Journal:  J Pharmacol Exp Ther       Date:  2012-03-21       Impact factor: 4.030

Review 5.  Disentangling the nature of the nicotine stimulus.

Authors:  Rick A Bevins; Scott T Barrett; Robert J Polewan; Steven T Pittenger; Natashia Swalve; Sergios Charntikov
Journal:  Behav Processes       Date:  2011-11-24       Impact factor: 1.777

6.  The effect of sazetidine-A and other nicotinic ligands on nicotine controlled goal-tracking in female and male rats.

Authors:  S Charntikov; A M Falco; K Fink; L P Dwoskin; R A Bevins
Journal:  Neuropharmacology       Date:  2016-10-17       Impact factor: 5.250

7.  Sex differences and the role of dopamine receptors in the reward-enhancing effects of nicotine and bupropion.

Authors:  Scott T Barrett; Trevor N Geary; Amy N Steiner; Rick A Bevins
Journal:  Psychopharmacology (Berl)       Date:  2016-10-01       Impact factor: 4.530

8.  Mecamylamine, dihydro-beta-erythroidine, and dextromethorphan block conditioned responding evoked by the conditional stimulus effects of nicotine.

Authors:  Amanda M Struthers; Jamie L Wilkinson; Linda P Dwoskin; Peter A Crooks; Rick A Bevins
Journal:  Pharmacol Biochem Behav       Date:  2009-09-22       Impact factor: 3.533

9.  Interoceptive conditioning with nicotine using extinction and re-extinction to assess stimulus similarity with bupropion.

Authors:  Sergios Charntikov; Nicole R deWit; Rick A Bevins
Journal:  Neuropharmacology       Date:  2014-07-28       Impact factor: 5.250

10.  The effect of switching pharmacological intervention during extinction on nicotine-evoked conditioned responding in rats.

Authors:  Steven T Pittenger; Lindsey C Zeplin; Linda P Dwoskin; Rick A Bevins
Journal:  Psychopharmacology (Berl)       Date:  2015-09-14       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.